Cargando…

A phase I study of TAS‐205 in patients with Duchenne muscular dystrophy

OBJECTIVE: Currently, the only approved standard Duchenne muscular dystrophy (DMD) treatment in Japan is oral steroids, which have various disadvantages. Previous work has suggested that hematopoietic‐type prostaglandin D synthase (HPGDS), involved in production of the inflammatory mediator prostagl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takeshita, Eri, Komaki, Hirofumi, Shimizu‐Motohashi, Yuko, Ishiyama, Akihiko, Sasaki, Masayuki, Takeda, Shin'ichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243382/ https://www.ncbi.nlm.nih.gov/pubmed/30480028 http://dx.doi.org/10.1002/acn3.651

Ejemplares similares

Early phase 2 trial of TAS‐205 in patients with Duchenne muscular dystrophy
por: Komaki, Hirofumi, et al.
Publicado: (2020)

Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches
por: Shimizu-Motohashi, Yuko, et al.
Publicado: (2019)

Modelling Duchenne muscular dystrophy in MYOD1-converted urine-derived cells treated with 3-deazaneplanocin A hydrochloride
por: Takizawa, Hotake, et al.
Publicado: (2019)

Publisher Correction: Modelling Duchenne muscular dystrophy in MYOD1-converted urine-derived cells treated with 3-deazaneplanocin A hydrochloride
por: Takizawa, Hotake, et al.
Publicado: (2020)

Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors
por: Miyatake, Shouta, et al.
Publicado: (2016)

Trends in steroid therapy for Duchenne muscular dystrophy in Japan
por: Takeuchi, Fumi, et al.
Publicado: (2016)

Systemic administration of the antisense oligonucleotide NS‐089/NCNP‐02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: Study protocol for a phase I/II clinical trial
por: Ishizuka, Takami, et al.
Publicado: (2023)

Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis
por: Shimizu-Motohashi, Yuko, et al.
Publicado: (2018)

Prednisolone improves walking in Japanese Duchenne muscular dystrophy patients
por: Takeuchi, Fumi, et al.
Publicado: (2013)

Exon-Skipping in Duchenne Muscular Dystrophy
por: Takeda, Shin’ichi, et al.
Publicado: (2021)

Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese national registry of muscular dystrophy (Remudy)
por: Nakamura, Harumasa, et al.
Publicado: (2013)

Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1/2 study
por: Komaki, Hirofumi, et al.
Publicado: (2020)

Clinical trial network for the promotion of clinical research for rare diseases in Japan: muscular dystrophy clinical trial network
por: Shimizu, Reiko, et al.
Publicado: (2016)

Mammalian Models of Duchenne Muscular Dystrophy: Pathological Characteristics and Therapeutic Applications
por: Nakamura, Akinori, et al.
Publicado: (2011)

Cardiac conduction disturbances and aging in patients with Duchenne muscular dystrophy
por: Segawa, Kazuhiko, et al.
Publicado: (2017)

Induction of Pluripotent Stem Cells from a Manifesting Carrier of Duchenne Muscular Dystrophy and Characterization of Their X-Inactivation Status
por: Miyagoe-Suzuki, Yuko, et al.
Publicado: (2017)

Left Ventricular End-Diastolic Diameter and Cardiac Mortality in Duchenne Muscular Dystrophy
por: Segawa, Kazuhiko, et al.
Publicado: (2020)

NS-065/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy
por: Watanabe, Naoki, et al.
Publicado: (2018)

Childhood‐onset cerebellar ataxia in Japan: A questionnaire‐based survey
por: Ono, Hiroya, et al.
Publicado: (2019)

Current Challenges and Future Directions in Recombinant AAV-Mediated Gene Therapy of Duchenne Muscular Dystrophy
por: Okada, Takashi, et al.
Publicado: (2013)

Comparison of Experimental Protocols of Physical Exercise for mdx Mice and Duchenne Muscular Dystrophy Patients
por: Hyzewicz, Janek, et al.
Publicado: (2015)

A novel LMNA mutation identified in a Japanese patient with LMNA-associated congenital muscular dystrophy
por: Ishiyama, Akihiko, et al.
Publicado: (2018)

Angiogenesis as a novel therapeutic strategy for Duchenne muscular dystrophy through decreased ischemia and increased satellite cells
por: Shimizu-Motohashi, Yuko, et al.
Publicado: (2014)

Long-term Observation in Patients with Duchenne Muscular Dystrophy with Early Introduction of a Standing Program Using Knee–ankle–foot Orthoses
por: Fujimoto, Akiko, et al.
Publicado: (2023)

Inhibition of FLT1 ameliorates muscular dystrophy phenotype by increased vasculature in a mouse model of Duchenne muscular dystrophy
por: Verma, Mayank, et al.
Publicado: (2019)

Exon 44 skipping in Duchenne muscular dystrophy: NS-089/NCNP-02, a dual-targeting antisense oligonucleotide
por: Watanabe, Naoki, et al.
Publicado: (2023)

Characteristics of Japanese Patients with Becker Muscular Dystrophy and Intermediate Muscular Dystrophy in a Japanese National Registry of Muscular Dystrophy (Remudy): Heterogeneity and Clinical Variation
por: Mori-Yoshimura, Madoka, et al.
Publicado: (2018)

The nSMase2/Smpd3 gene modulates the severity of muscular dystrophy and the emotional stress response in mdx mice
por: Matsuzaka, Yasunari, et al.
Publicado: (2020)

Dental pulp stem cells can improve muscle dysfunction in animal models of Duchenne muscular dystrophy
por: Nitahara-Kasahara, Yuko, et al.
Publicado: (2021)

Mitochondria mediate cell membrane repair and contribute to Duchenne muscular dystrophy
por: Vila, Maria C, et al.
Publicado: (2017)

Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases
por: Tsoumpra, Maria K., et al.
Publicado: (2019)

Mutation-independent Proteomic Signatures of Pathological Progression in Murine Models of Duchenne Muscular Dystrophy
por: van Westering, Tirsa L. E., et al.
Publicado: (2020)

Inflammatory predisposition predicts disease phenotypes in muscular dystrophy
por: Nitahara-Kasahara, Yuko, et al.
Publicado: (2016)

Initial Pulmonary Respiration Causes Massive Diaphragm Damage and Hyper-CKemia in Duchenne Muscular Dystrophy Dog
por: Nakamura, Akinori, et al.
Publicado: (2013)

Survival in Duchenne muscular dystrophy
por: RALL, SUSANNE, et al.
Publicado: (2012)

Theragnosis for Duchenne Muscular Dystrophy
por: Luce, Leonela, et al.
Publicado: (2021)

Efficacy of Prednisolone in Generated Myotubes Derived From Fibroblasts of Duchenne Muscular Dystrophy Patients
por: Kameyama, Tsubasa, et al.
Publicado: (2018)

Hypokalemia complicating Duchenne muscular dystrophy.
por: McDonald, B., et al.
Publicado: (1987)

The role of fibrosis in Duchenne muscular dystrophy
por: KLINGLER, WERNER, et al.
Publicado: (2012)

Delay in Diagnosis of Duchenne Muscular Dystrophy
por: Rao, Vamshi K., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ui75v2hpms5t0jdqogsnev0pdf